📊 DNLI Key Takeaways
Is Denali Therapeutics Inc. (DNLI) a Good Investment?
Denali Therapeutics is a pre-revenue biopharmaceutical company with severe profitability challenges, burning cash at an unsustainable rate of $412.6M annually with negative free cash flow of $422.1M. While the company maintains adequate liquidity with $205.3M cash and a strong balance sheet with minimal debt, the trajectory of operating losses (-$555.3M) and accelerating net losses (-$512.5M, worsening 21.2% YoY) indicates fundamental business model execution problems.
Denali Therapeutics remains a pre-revenue biotech with substantial operating and free cash flow losses, and profitability trends are deteriorating as net losses widened year over year. While the balance sheet is currently strong with high liquidity, no long-term debt, and over $1.0B in equity, the core fundamental question is whether the company can convert R&D spending into durable commercial or partnership revenue before cash burn materially weakens financial flexibility.
Why Buy Denali Therapeutics Inc. Stock? DNLI Key Strengths
- Strong balance sheet with $1.0B stockholders equity and minimal debt ($0B long-term debt)
- Excellent liquidity position with $205.3M cash and 9.16x current ratio providing runway for operations
- Significant asset base of $1.1B suggests substantial drug pipeline and development infrastructure in place
- Very strong liquidity profile with 9.16x current and quick ratios
- Debt-free capital structure reduces financial distress risk
- Large equity base and modest liabilities provide balance sheet support
DNLI Stock Risks: Denali Therapeutics Inc. Investment Risks
- Severe cash burn of $412.6M operating cash flow with negative free cash flow of $422.1M indicating unsustainable R&D spending relative to pipeline progress
- Zero revenue with substantial operating losses of $555.3M and worsening net losses (-21.2% YoY) signals either failed clinical trials or major commercialization delays
- Negative ROE of -50.6% and ROA of -44.8% demonstrate severe capital inefficiency with stockholders equity being destroyed at accelerating rates
- At current cash burn rates, $205.3M cash runway is only ~6 months, forcing equity dilution or major asset sales
- Zero revenue means the business is still fully dependent on external funding or existing cash reserves
- Operating cash burn is very high, with negative free cash flow of roughly $422M
- Net losses worsened year over year, indicating weak near-term profitability trajectory
Key Metrics to Watch
- Revenue inflection timing - when first drug achieves FDA approval and commercial launch
- Quarterly operating cash burn trend - whether burn rate is stabilizing or continuing to worsen
- Cash balance and runway - exact timeline until need for capital raise or critical milestones required for financing
- Clinical trial progress - advancement of lead candidates through development pipeline stages
- Quarterly cash burn relative to cash and equivalents
- Any sustained revenue generation from product commercialization or collaboration milestones
Denali Therapeutics Inc. (DNLI) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 9.16x current ratio provides a solid financial cushion.
DNLI Profit Margin, ROE & Profitability Analysis
DNLI vs Healthcare Sector: How Denali Therapeutics Inc. Compares
How Denali Therapeutics Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Denali Therapeutics Inc. Stock Overvalued? DNLI Valuation Analysis 2026
Based on fundamental analysis, Denali Therapeutics Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Denali Therapeutics Inc. Balance Sheet: DNLI Debt, Cash & Liquidity
DNLI Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Denali Therapeutics Inc.'s revenue has remained relatively flat over the 5-year period, with a 1% decline. The most recent EPS of $-1.06 indicates the company is currently unprofitable.
DNLI Revenue Growth, EPS Growth & YoY Performance
DNLI Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2024 | N/A | -$25.8M | $-0.19 |
| Q2 2024 | N/A | $73.6M | $0.52 |
| Q1 2024 | N/A | -$101.8M | $-0.68 |
| Q3 2023 | $184.0K | -$25.8M | $-0.19 |
| Q2 2023 | $52.5M | -$58.8M | $-0.48 |
| Q1 2023 | $35.1M | -$65.2M | $-0.53 |
| Q3 2022 | $184.0K | -$84.6M | $-0.69 |
| Q2 2022 | $22.9M | -$58.8M | $-0.48 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Denali Therapeutics Inc. Dividends, Buybacks & Capital Allocation
DNLI SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Denali Therapeutics Inc. (CIK: 0001714899)
📋 Recent SEC Filings
❓ Frequently Asked Questions about DNLI
What is the AI rating for DNLI?
Denali Therapeutics Inc. (DNLI) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 86% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are DNLI's key strengths?
Claude: Strong balance sheet with $1.0B stockholders equity and minimal debt ($0B long-term debt). Excellent liquidity position with $205.3M cash and 9.16x current ratio providing runway for operations. ChatGPT: Very strong liquidity profile with 9.16x current and quick ratios. Debt-free capital structure reduces financial distress risk.
What are the risks of investing in DNLI?
Claude: Severe cash burn of $412.6M operating cash flow with negative free cash flow of $422.1M indicating unsustainable R&D spending relative to pipeline progress. Zero revenue with substantial operating losses of $555.3M and worsening net losses (-21.2% YoY) signals either failed clinical trials or major commercialization delays. ChatGPT: Zero revenue means the business is still fully dependent on external funding or existing cash reserves. Operating cash burn is very high, with negative free cash flow of roughly $422M.
What is DNLI's revenue and growth?
Denali Therapeutics Inc. reported revenue of $0.0.
Does DNLI pay dividends?
Denali Therapeutics Inc. does not currently pay dividends.
Where can I find DNLI SEC filings?
Official SEC filings for Denali Therapeutics Inc. (CIK: 0001714899) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is DNLI's EPS?
Denali Therapeutics Inc. has a diluted EPS of $-2.97.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is DNLI a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Denali Therapeutics Inc. has a SELL rating with 86% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is DNLI stock overvalued or undervalued?
Valuation metrics for DNLI: ROE of -50.6% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy DNLI stock in 2026?
Our dual AI analysis gives Denali Therapeutics Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is DNLI's free cash flow?
Denali Therapeutics Inc.'s operating cash flow is $-412.6M, with capital expenditures of $9.5M.
How does DNLI compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -50.6% (avg: 15%), current ratio 9.16 (avg: 2).